Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Azacitidine and Pembrolizumab for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Acute Myeloid Leukemia

Trial Status: active

This phase II trial studies how well azacitidine and pembrolizumab work to shrink tumors in patients with Hodgkin lymphoma and acute myeloid leukemia that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving azacitidine and pembrolizumab may help control Hodgkin lymphoma and acute myeloid leukemia in patients.